AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02961101
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy be given depends on the cancer type and treatment regimen before enrollment.
Trial: NCT00520806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion for 48 h
Trial: NCT01728376
Drug: Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
Trial: NCT01018810
Drug: LY2525623 Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously at randomization and every 2 weeks for 6 weeks
Trial: NCT01018810
Drug: LY2525623 Subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered subcutaneously at randomization and every 2 weeks for 6 weeks
Trial: NCT01018810
Drug: Placebo Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously at randomization and every 2 weeks for 6 weeks
Trial: NCT01018810
Drug: Placebo Subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered subcutaneously at randomization and every 2 weeks for 6 weeks
Trial: NCT04303065
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The preparation and conditioning of the placebo capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).
Trial: NCT02657408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04749173
Drug: DWRX2003, 96mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Intramuscularly injection at predefined injection sites
Trial: NCT04749173
Drug: DWRX2003, 144mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Intramuscularly injection at predefined injection sites
Trial: NCT01009073
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-263 is taken orally.~Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed.
Trial: NCT01009619
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 250 mg daily during 5 days followed by 250 mg three times a week on Mon., Wed. and Fri. during study-period.
Trial: NCT01009619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily during 5 days, followed by one placebo three times a week on Mon., Wed. and Fri during rest of study-period.
Trial: NCT04044001
Drug: Rifafour e-275®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifafour e-275® (150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, 275 mg ethambutol per tablet)
Trial: NCT01231880
Drug: Placebo given every month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active ingredient
Trial: NCT00438568
Drug: Regular Insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intra-nasally twice a day for 16 weeks
Trial: NCT00438568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intra-nasally twice a day for 16 weeks
Trial: NCT00136188
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration of folic acid 5mg /d for 4 weeks
Trial: NCT00511368
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04490915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active dosage form
Trial: NCT02791763
Drug: 6 mg GSK1278863 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.
Trial: NCT02048319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution, injected as placebo
Trial: NCT00604760
Drug: Placebo for MEM 3454
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule once a day
Trial: NCT00770159
Drug: Comparator: placebo to MK0822
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panel A: placebo to MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: placebo to MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: placebo to MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: placebo to MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: placebo to MK0822 tablets 100 mg once weekly for 6 weeks.
Trial: NCT00302068
Drug: Placebo Pill.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill, daily, for 16 weeks.
Trial: NCT02325206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one administration in the morning
Trial: NCT01032889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline placebo for injection
Trial: NCT03204006
Drug: sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline preinduction
Trial: NCT01489306
Drug: MDT-637
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled doses of MDT-637 over a 10 day period
Trial: NCT03415711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sachets with maltose, cornstarch and dioxide
Trial: NCT01383148
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered starting on D1 of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by SC injections and then once every 3 weeks until progression or discontinuation due to any reason.~* First line therapy: as in Arm 1~* Maintenance therapy: as in Arm 1
Trial: NCT03195309
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
Trial: NCT02707263
Drug: intravenous continuous infusion of heparin (IV UFH)
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02707263
Drug: Subcutaneous Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02978599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily for 5 days
Trial: NCT03592082
Drug: standard antibiotic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic therapy administered per standard protocol
Trial: NCT03445949
Drug: 6 months treatment with a single antiplatelet agent
RxNorm normalized name: Detoxifying agents for antineoplastic treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuing single antiplatelet agent up until 6 months
Trial: NCT03586570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets matching aprocitentan tablets
Trial: NCT02703337
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (SC)
Trial: NCT01039103
Drug: PEG-liposomal prednisolone sodium phosphate
RxNorm normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone phosphate (DB14631)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
Trial: NCT02152917
Drug: Floseal®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03113500
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03113500
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03113500
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00746512
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone placebo tablets once daily for 15 days.
Trial: NCT00746512
Drug: Placebo Over-Encapsulated Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
Trial: NCT01449799
Drug: GSK961081 800 microgram dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be provided via a combination of 4 inhalers - one 400 micrograms GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers
Trial: NCT02207426
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01453296
Drug: GW642444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW642444 25 μg; Novel dry powder inhaler
Trial: NCT01453296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo; Novel dry powder inhaler
Trial: NCT02894268
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 100g po bid
Trial: NCT02894268
Drug: Sensitivity antibiotics
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two antibiotics based on antibiotic sensitivity of H.pylori culture, including amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline and furazolidone.
Trial: NCT01085006
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranexamic acid in cases, normal saline in controls
Trial: NCT02182388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01763008
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Doripenem will be administered as per the recommended dose, ie, 500 mg, intravenously (ie, in the vein), for every 8 hours. Duration of treatment with doripenem: for nosocomial pneumonia including ventilator-associated pneumonia patients: 7 to 14 days; for complicated intra-abdominal infection patients: 5 to 14 days; for complicated urinary tract infection, including pyelonephritis (bacterial infection of the kidneys) patients: 10 days.
Trial: NCT04154813
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine was increased from 20mg/d to the target dose (60mg/d) or below the maximum tolerable dose within 2 weeks.
Trial: NCT03901352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets for oral administration
Trial: NCT02641561
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which is commonly used to reduce inflammation caused by gout, osteoarthritis and rheumatoid arthritis. It acts by blocking the cyclo-oxygenase 1 and 2 (COX) receptors. It has also been implicated to prevent post-ERCP pancreatitis
Trial: NCT01703481
Drug: JNJ-42756493: Part 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 0.5 mg (starting dose) capsule of JNJ-42756493 orally (by mouth) once daily on Day 1 of Cycle 1. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RP2D).
Trial: NCT01703481
Drug: JNJ-42756493: Part 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-42756493 at the RP2D or below RP2D (maximum tolerated dose from Part 1) orally once daily on a 21 days cycle to confirm RP2D (in Part 2).
Trial: NCT01595399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an equivalent volume of normal saline to atropine IV
Trial: NCT00762073
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension matching budesonide
Trial: NCT01703481
Drug: JNJ-42756493: Part 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.
Trial: NCT01703481
Drug: JNJ-42756493: Part 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.
Trial: NCT02641561
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard IVF would include 0.9% normal saline (NS) solution used during all endoscopic procedures. 0.9% NS includes equal parts sodium and chloride.
Trial: NCT00595946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mcg capsules twice daily (BID)
Trial: NCT02325739
Drug: FGF401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGF401 is a FGFR4 inhibitor.
Trial: NCT02317796
Drug: MLR-1023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
Trial: NCT02334046
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .
Trial: NCT02334046
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .
Trial: NCT02641561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo would be a suppository 50 mg x 2
Trial: NCT03114540
Drug: GBT440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03079102
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An endogenous gaseous signaling molecule which stimulates soluble guanylate cyclase and may act via S-nitrosation, nitrite/nitrate or nitrated fatty acid formation.
Trial: NCT02206789
Drug: Prednisolone acetate1%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
Trial: NCT04203862
Drug: NPC-22
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of low dose NPC-22
Trial: NCT04203862
Drug: NPC-22
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of low/middle dose NPC-22
Trial: NCT04203862
Drug: NPC-22
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of middle dose NPC-22
Trial: NCT04203862
Drug: NPC-22
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of middle/high dose NPC-22
Trial: NCT04203862
Drug: NPC-22
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of high dose NPC-22
Trial: NCT03096457
Drug: Paromomycin Sulfate
RxNorm normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical application 2 times a day during 20 days
Trial: NCT03865550
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02182076
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of BIBF 1120 ES soft gelatine capsules
Trial: NCT02871869
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
Trial: NCT00003013
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003013
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003013
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003013
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003013
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02871869
Drug: Cinobufacini Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities
Trial: NCT02057549
Drug: Conventional Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
Trial: NCT04867980
Drug: ACP-196
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of 100 mg ACP-196 (1 x 100 mg capsule) on Day 1 (Treatment A) and 400 mg ACP-196 (4 x 100 mg capsules) on Day 1 (Treatment B) according to the randomization scheme.
Trial: NCT04867980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of ACP-196 matching placebo (4 x 100 mg matching placebo capsules) and moxifloxacin matching placebo (1 x 400 mg matching placebo tablet) on Day 1 (Treatment D) according to the randomization scheme.
Trial: NCT01257061
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion
Trial: NCT01257061
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion
Trial: NCT02181075
Drug: ThermoDox® (LTLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ThermoDox® (LTLD) infusion at a dose of 50mg/m2 whilst under general anaesthetic during intervention (Day 1)
Trial: NCT01235741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.
Trial: NCT03206229
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
Trial: NCT01017380
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celecoxib 400 mg 1 cap before surgery
Trial: NCT01017380
Drug: etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg 1 tab before surgery
Trial: NCT02365701
Drug: Motilitone 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks
Trial: NCT02365701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.
Trial: NCT01047605
Drug: Neurapas balance
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 tablets single dose
Trial: NCT01047605
Drug: Pascoflair 425 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets , single dose
Trial: NCT01047605
Drug: P-Tabletten weiß
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets, single dose
Trial: NCT00611403
Drug: Artificial Tears REFRESH ENDURA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REFRESH ENDURA® administered twice daily in each eye for 6 months following LASIK surgery
Trial: NCT01745822
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
Trial: NCT00543959
Drug: MK0533
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.